Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)

Inclusion Criteria: * Male patient * Between 45 and 85 years old. * Patient with bothersome lower urinary tract symptoms such as pollakiuria (daytime or night time), urgency, sensation of incomplete voiding, delayed urination or weak stream, existing for over 12 months * I-PSS ≥ 10 at selection visit and ≥ 12 at randomisation visit (visit 2) * Stable patient's disease at randomisation defined as an absolute difference of 2 or less on I-PSS between selection and randomisation visits (visit 1 and visit 2) * I-PSS QoL score ≥ 3 evaluated at selection and randomisation visits, * 5 mL/s ≤ maximum urinary flow rate \< 15 mL/s for a voided volume ≥ 150 mL and ≤ 500 mL evaluated at randomisation visit (2 measurements if necessary) * Prostatic volume ≥30 cm³ determined by transrectal ultrasound at randomisation visit (visit 2) * Serum total PSA at randomisation visit (visit 2) : * 4 ng/mL * 10 ng/mL and Prostate Specific Antigen (free) / Prostate Specific Antigen (total) ≥ 25% or negative prostate biopsy within the past 6 months prior to selection visit. * Patient able to understand and sign the informed consent and understand and fill in self-questionnaires Exclusion Criteria: * Post-void residual urine volume \> 200 mL (by suprapubic ultrasound) at randomisation visit (visit 2). * Urological history : * Urethral stricture disease and/or bladder neck disease * Active (at selection and randomisation visits) or recent (\< 3 months) or recurrent urinary tract infection * Indication of BPH surgery * Stone in bladder or urethra * Acute or chronic (documented) prostatitis * Prostate and cancer cancer treated or untreated * Interstitial cystitis (documented by symptoms and/or biopsy) * Active upper tract stone disease causing symptoms * Patient with history of surgery of the prostate, bladder neck or pelvic region * Any local and/or systemic inflammation disorders at selection and randomisation visit